CSIMarket


Pfizer Inc  (PFE)
Other Ticker:  
 


 

Pfizer Inc

PFE's Financial Statements and Analysis



Pfizer Inc reported in the forth quarter of 2023 net loss per share of $-0.59 compare to earnings per share of $0.87 in the same quarter a year ago a decrease compare to $-0.42 realized in previous quarter.


forth quarter of 2023
Earnings Per Share Revenues
$ -0.59 $  14,248 Mill
$-1.46     $-10,041M     -41.34 %



Pfizer Inc's Revenue fell by -41.34 % in forth quarter of 2023 (Dec 31 2023) year on year, to $14,248 million and advanced by 7.68 % sequentially.


Pfizer Inc is Expected to report next financial results on May 01, 2024.

More on PFE's Income Statement



Pfizer Inc's in theforth quarter of 2023 recorded net loss of $-3,360.000 million, compare to net income of $5,003.000 million achieved in IV. Quarter a year ago.

Sequentially net loss advanced

More on PFE's Growth

Pfizer Inc Inventories
Inventories grew by 13.45 % to $10,189 million from IV. Quarter a year ago, sequentially inventories fell by -0.15 %. In Dec 31 2023 company's net cash and cash equivalents decreased by $-316 million, capital expenditures fell by -10014.30%, to $-1,044 millions compare to same quarter a year ago

More on PFE's Cash flow Statement


Pfizer Inc payed out dividend of $1.62 per share in last 52 weeks representing 437.84 % of net earning per share in trailing twelve-month period.

During the same period Pfizer Inc earned $ 1.52 cash per share, on a free-cash flow basis 410.57 % of net earning per share.

Book value fell by -9.44 % sequentially to $15.59 per share.


Company issued 81.03 million shares or 1.44 % in Dec 31 2023.
Debt Coverage Ratio was 0.02.

More on PFE's Dividends

 Market Capitalization (Millions) 160,042
 Shares Outstanding (Millions) 5,727
 Total Debt (Millions $) 71,888
 Revenue (TTM) (Millions $) 58,496
 Net Income (TTM) (Millions $) 2,158
 Cash Flow (TTM) (Millions $) 2,448
 Capital Exp. (TTM) (Millions $) -3,907
 Dividend TTM ($) 1.62 $
 Dividend Yield TTM (%) 5.8 %
 Employees (TTM) $ 79,000




Pfizer Inc payed out dividend of $1.62 per share in the last 52 weeks representing 437.84 % of net earning per share in trailing twelve-month period.

During the same period Pfizer Inc had $ 1.52 cash flow per share, on a free-cash flow basis 410.57 % of net earning per share.

Book value fell by -9.44 % sequentially to $15.59 per share.


Company issued 81.03 million shares or 1.44 % in Dec 31 2023.
Debt Coverage Ratio was 0.02.

More on PFE's Balance Sheets

 Market Capitalization (Millions) 160,042
 Shares Outstanding (Millions) 5,727
 Total Debt (Millions $) 71,888
 Revenue (TTM) (Millions $) 58,496
 Net Income (TTM) (Millions $) 2,158
 Cash Flow (TTM) (Millions $) 2,448
 Capital Exp. (TTM) (Millions $) -3,907
 Dividend TTM ($) 1.62 $
 Dividend Yield TTM (%) 5.8 %
 Employees (TTM) $ 79,000
   


  News about Pfizer Inc Earnings

Pfizer Inc. Faces Financial Challenges: Revenue Crumbles in Fiscal Fourth Quarter of 2023

Pfizer Inc. has faced some challenging times recently, as reflected in its financial results for the fiscal fourth quarter of 2023. The company reported a loss per stock of $-0.59 per share, a significant decrease compared to $0.87 per share from the previous year. This is also an increase in loss from the preceding financial reporting period, where it experienced a loss of $-0.42 per share.
Additionally, Pfizer Inc. witnessed a decline in revenue of -41.34% to $14.25 billion from $24.29 billion in the same period a year prior. However, there was a sequential revenue growth of 7.678% from $13.23 billion. Furthermore, the company reported a net loss of $-3,360.000 million for the fiscal fourth quarter of ...

PFE's Revenue Takes a Shocking Plunge: A Defining Moment for Pfizer Inc's Fiscal Period Ending October 01, 2023

The disappointing financial results announced by the Major Pharmaceutical Preparations company for August to October 01, 2023, reveal a significant decline in revenue of -41.55% to only $13.23 billion. This downturn is alarming and raises concerns about the overall health of the company. Additionally, Pfizer Inc recorded a shortfall per share of $-0.42, compared to $1.51 in the same period the previous year, indicating a notable decrease in profitability.
In contrast, the rest of the Major Pharmaceutical Preparations sector experienced a top-line gain in the third quarter of 2023, further highlighting Pfizer Inc's underperformance. This relative decline in earnings per share compared to the previous repo...

Pfizer Inc Announces Substantial Revenue Decline Throughout Sophisticated Fiscal Quarter Ending July 02, 2023



Pfizer Inc, the renowned pharmaceutical giant, is currently facing significant challenges as its most recent financial results indicate a sharp decline in profitability and revenue. The company's net profit per share has plummeted by a staggering 76.3%, while its revenue experienced a drastic decrease of 54.098% compared to the same reporting period a year ago. Alongside these concerning figures, Pfizer's operating margin has also been adversely affected, deteriorating to 15.34%. These indicators suggest a bearish outlook for the company, raising concerns among investors and analysts.
Dramatic Decline in Net Profit and Revenue:
Pfizer Inc's net profit per share has dropped by an alarming 76...

Pfizer Inc's Financial Slump Continues: Profits Plunge and Revenue Falters in First Quarter of 2023

Pfizer Inc, the world-renowned pharmaceutical company, has been experiencing a major slump in its financial performance over the past few quarters. The company recently declared soft top and bottom-line results for the February to April 2023 financial period, where the net profit per share plummeted by a staggering 35.76% and revenue fell by 19.242% year on year. This significant decline in financials is a clear indication of troubling times ahead for the company.
The sharp drop in net profit per share and revenue for the period is concerning, as the company has failed to meet investor expectations. Revenue for the period fell to $18.28 billion compared to $22.64 billion in the corresponding period a yea...


Date modified: 2024-02-22T21:18:52+00:00





Help

About us

Advertise

CSIMarket Company, Sector, Industry, Market Analysis, Stock Quotes, Earnings, Economy, News and Research. 
   Copyright © 2024 CSIMarket, Inc. All rights reserved. This site uses cookies to make your browsing experince better. By using this site, you agree to the Terms of Service and Privacy Policy - UPDATED (Read about our Privacy Policy)

Intraday data delayed per exchange requirements. All quotes are in local exchange time. Intraday data delayed 15 minutes for Nasdaq, and other exchanges. Fundamental and financial data for Stocks, Sector, Industry, and Economic Indicators provided by CSIMarket.com